Agios (AGIO) Q2 Revenue Jumps 45%

Core Insights - Agios Pharmaceuticals reported a notable revenue beat in Q2 2025, with GAAP net product revenue of $12.5 million for its lead product PYRUKYND, reflecting strong sales momentum despite increasing costs as the company prepares for major regulatory events and product launches [1][5] Financial Performance - EPS (GAAP) for Q2 2025 was $(1.93), a decline of 14.2% year-over-year from $(1.69) in Q2 2024 [2] - Revenue (GAAP) reached $12.5 million, up 45.4% from $8.6 million in Q2 2024 [2] - Net loss increased to $(112.0 million), a rise of 16.5% compared to $(96.1 million) in Q2 2024 [2][8] - R&D expenses rose to $91.9 million, an increase of 18.7% from $77.4 million in Q2 2024 [2] - SG&A expenses increased by 29.3% to $45.9 million, driven by preparations for regulatory approvals [2][6] Business Overview and Strategy - Agios specializes in therapies for rare blood disorders, focusing on high unmet needs, with PYRUKYND targeting pyruvate kinase deficiency [3] - The company aims to expand PYRUKYND's reach to other rare diseases, including thalassemia and sickle cell disease, through clinical trials and regulatory filings [3] Regulatory and Commercial Developments - The company is preparing for a key regulatory milestone with a PDUFA goal date of September 7, 2025, for PYRUKYND's approval in thalassemia [6][7] - Agios has established a European distribution partnership with Avanzanite Bioscience to launch PYRUKYND across Europe and the UK [6] - The FDA is currently reviewing the application for PYRUKYND in thalassemia, with late-stage trial results for sickle cell disease expected by year-end [7][9] Pipeline and Future Outlook - PYRUKYND product revenue grew 44.6% year-over-year, with unique patients enrolling for treatment reaching 248, a 6% increase from the prior quarter [5] - The company closed the quarter with $1.34 billion in cash and marketable securities, a decrease from year-end 2024 [8] - Management did not provide detailed financial guidance for fiscal 2025 but indicated that the current liquidity position supports plans for new launches and ongoing research investments [10]